Nippon Chemiphar Turns The Tide With Increase In Generics Sales
As Company Reports Increase In Net Revenues And Decrease In Operating Loss
Japan’s Nippon Chemiphar has reported a year-on-year increase in generics sales and net revenues in the first quarter of FY21, after seeing back-to-back underwhelming quarters due to reasons such as recent National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.
You may also be interested in...
Nippon Chemiphar’s Generics Business Continues To Recover
Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.
Nippon Chemiphar Successfully Reverses Decline
Japan’s Nippon Chemiphar gets a grip on a decline in pharmaceutical sales seen earlier this year, on the back of strong sales of generic drugs launched last year. The company also expects an upward impact from expanded sales of generic drugs achieved through sales channel diversification efforts for its current financial year ending 31 March 2022.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.